Actively Recruiting
Remote Ischaemic Conditioning in STEMI Patients in AFRICA
Led by University of Cape Town · Updated on 2025-04-03
1400
Participants Needed
20
Research Sites
311 weeks
Total Duration
On this page
Sponsors
U
University of Cape Town
Lead Sponsor
G
Groote Schuur Hospital, South Africa
Collaborating Sponsor
AI-Summary
What this Trial Is About
The RIC-AFRICA trial is a multi-centre, sham-controlled, randomised controlled trial (RCT) involving 1400 ST-segment elevation myocardial infarction (STEMI) patients presenting within ≤ 24 hours of myocardial infarction (MI) onset, across approximately 25 sites in 7 African countries (South Africa, Kenya, Sudan, Uganda, Mozambique, Senegal and Mauritius). Patients presenting with STEMI and deemed ineligible for the RIC AFRICA RCT because they present \>24 hours from MI onset but less than 72 hours, will be recruited into the observational arm of the study with the same endpoints as the trial. The purpose of the RCT is to determine whether Remote Ischaemic Conditioning (RIC) can reduce the rates of all-cause death and early post-myocardial heart failure at 30-days in STEMI patients treated predominantly with thrombolytic therapy.
CONDITIONS
Official Title
Remote Ischaemic Conditioning in STEMI Patients in AFRICA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (18 years or older) with suspected STEMI showing specific ECG changes
- Presentation within 24 hours of myocardial infarction onset as judged by the clinician
- Signed informed consent
- For observational arm: patients with STEMI presenting between 24 and 72 hours after chest pain onset with compatible clinical, biomarker, ECG, or echocardiographic evidence
You will not qualify if you...
- Patients planned for primary percutaneous coronary intervention
- Patients with cardiogenic shock or haemodynamic instability defined by low blood pressure, need for support, and signs of organ damage
- Patients with severe active skin disease, burns, bilateral arm amputations, acute limb ischaemia, upper limb gangrene, breast cancer with lymph-node involvement on the side of RIC, or bilateral arteriovenous fistulae
- Patients with other diseases limiting life expectancy to less than 24 hours
- Patients with contraindications to thrombolytic therapy if presenting within 12 hours
- Patients refusing or unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Coast General Teaching Hospital
Mombasa, Mombasa County, Kenya
Actively Recruiting
2
Mombasa Hospital
Mombasa, Mombasa County, Kenya
Actively Recruiting
3
Kenyatta National Hospital
Nairobi, Nairobi County, Kenya
Actively Recruiting
4
Nairobi West hospital
Nairobi, Kenya
Actively Recruiting
5
Hospital Central de Mpauto
Maputo, Mozambique
Actively Recruiting
6
Hopital Principal de Dakar
Dakar, Senegal
Actively Recruiting
7
Charlotte Maxeke Hospital
Johannesburg, Gauteng, South Africa, 2193
Actively Recruiting
8
Wentworth Hospital
Durban, KwaZulu-Natal, South Africa, 4026
Actively Recruiting
9
Tshepong Hospital
Klerksdorp, North West, South Africa, 2574
Actively Recruiting
10
Mitchell's Plain District Hospital
Cape Town, Western Cape, South Africa, 7785
Actively Recruiting
11
Groote Schuur Hospital
Cape Town, Western Cape, South Africa, 8000
Actively Recruiting
12
Victoria Hospital
Cape Town, Western Cape, South Africa, 8000
Actively Recruiting
13
George Hospital
George, Western Cape, South Africa, 6530
Actively Recruiting
14
Al Saha Specialised Hospital
Khartoum, Khartoum State, Sudan
Actively Recruiting
15
Al Shaab Teaching Hospital
Khartoum, Khartoum State, Sudan
Actively Recruiting
16
Sudan Heart Centre
Khartoum, Khartoum State, Sudan
Actively Recruiting
17
The Royal Care International Hospital
Khartoum, Khartoum State, Sudan
Actively Recruiting
18
Aliaa Specialist Hospital
Omdurman, Omdurman, Sudan
Actively Recruiting
19
Medani Heart Centre
Wad Medani, Sudan
Actively Recruiting
20
Uganda Heart Institute
Kampala, Kampala, Uganda
Actively Recruiting
Research Team
K
Kishal Lukhna, MBChB
CONTACT
S
Sara Giesz
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here